Shares in Mainstay Medical, the Irish medical device company targeting chronic back pain, crashed to record lows after a key clinical trial failed.

Shares in Mainstay Medical, the Irish medical device company targeting chronic back pain, crashed to record lows after a key clinical trial failed. M(...)

The ReActiv8 unit is designed to treat disabling pain in patients with chronic lower back pain through the use of an implant that stimulates nerves to strengthen muscles in the lower back

Mainstay Medical expects results from a critical trial for its Reactiv8 device for people who suffer disabling chronic lower back pain by the end of t(...)

Alex Hobbs, chairman and Sarah-Jane Larkin, director general, Irish Venture Capital Association. The IVCA has urged the Government to act following weak investment figures. Photograph: Colm Mahady/Fennell Photography

Venture capital funding into Irish tech firms fell by 9 per cent in the first half of 2018, the first time that the funding has fallen since 2011. Th(...)

Matthew Onaitis assumed the role of chief financial officer at Mainstay Medical on August 20th.

Irish-headquartered medical device company Mainstay Medical has appointed Matthew Onaitis as chief financial officer, assuming the role from Hugh Kava(...)

The ReActiv8 unit is designed to treat disabling pain in patients with chronic lower back pain through the use of an implant that stimulates nerves to strengthen muscles in the lower back

Back pain group Mainstay Medical has successfully implanted 204 patients with its Reactiv8 device as part of a clinical trial to access the key United(...)

The ReActiv8 implant.

Mainstay Medical has suffered a setback in its efforts to get its ReActiv8 implant approved for therapeutic use in Australia, with regulators requesti(...)

ReActiv8 is designed to treat chronic low back pain

Irish medical device firm Mainstay Medical International has raised €30.1 million through a new share placing as it pushes to commercialise its back (...)

Mainstay Medical’s  ReActiv8 device for the treatment of chronic low back pain

Mainstay Medical has passed an “important milestone” on winning access to the key US market for its new implant therapy for people suffering from chro(...)

Mainstay Medical chief executive Peter Crosby; he  will stand down in October of this year. Photograph: Nick Bradshaw

Losses at Dublin-based Mainstay Medical have continued to mount for the first half of 2017. The group reported a loss of $13.27 million (€11.17m) fo(...)

Mainstay Medical chief executive Peter Crosby: “our existing investor group is very supportive of Mainstay”

Dublin-listed Mainstay Medical, a company that is targeting chronic back pain with an implantable device, is expecting to seek further funding in the (...)

  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »